Search hospitals > Arkansas > Springdale
Highlands Oncology Group
Claim this profileSpringdale, Arkansas 72762
Global Leader in Non-Small Cell Lung Cancer
Global Leader in Breast Cancer
Conducts research for Tumors
Conducts research for Lung Cancer
Conducts research for Cancer
104 reported clinical trials
8 medical researchers
Summary
Highlands Oncology Group is a medical facility located in Springdale, Arkansas. This center is recognized for care of Non-Small Cell Lung Cancer, Breast Cancer, Tumors, Lung Cancer, Cancer and other specialties. Highlands Oncology Group is involved with conducting 104 clinical trials across 200 conditions. There are 8 research doctors associated with this hospital, such as J. Thaddeus Beck, Joseph T Beck, Eric S Schaefer, MD, and Joseph Thaddeus Beck.Area of expertise
1Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage III
BRAF positive
2Breast Cancer
Global LeaderStage IV
HER2 negative
Stage III
Top PIs
J. Thaddeus BeckHighlands Oncology Group11 years of reported clinical research
Studies Breast Cancer
Studies Melanoma
16 reported clinical trials
33 drugs studied
Joseph T BeckHighlands Oncology Group7 years of reported clinical research
Studies Breast Cancer
Studies Cancer
14 reported clinical trials
37 drugs studied
Eric S Schaefer, MDHighlands Oncology Group1 year of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
11 reported clinical trials
27 drugs studied
Joseph Thaddeus BeckHighlands Oncology Group2 years of reported clinical research
Studies Breast Cancer
Studies Tumors
6 reported clinical trials
22 drugs studied
Clinical Trials running at Highlands Oncology Group
Breast Cancer
Non-Small Cell Lung Cancer
Colorectal Cancer
Cancer
Solid Tumors
Tumors
Lung Cancer
Melanoma
Prostate Cancer
Lymphoma
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Imlunestrant
for Early Breast Cancer
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.
Recruiting2 awards Phase 36 criteria
Elacestrant
for Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of elacestrant over the course of 6 months in patients with ER+/HER2- advanced/metastatic breast cancer who received no prior CDK4/6i in the metastatic setting.
Recruiting1 award Phase 217 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Highlands Oncology Group?
Highlands Oncology Group is a medical facility located in Springdale, Arkansas. This center is recognized for care of Non-Small Cell Lung Cancer, Breast Cancer, Tumors, Lung Cancer, Cancer and other specialties. Highlands Oncology Group is involved with conducting 104 clinical trials across 200 conditions. There are 8 research doctors associated with this hospital, such as J. Thaddeus Beck, Joseph T Beck, Eric S Schaefer, MD, and Joseph Thaddeus Beck.